FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc

Resistance to epidermal growth factor receptor (EGFR) targeted monoclonal antibody therapy represents a clinical challenge in patients suffered from RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, the molecular mechanisms and key factors conferring this resistance are largely unknow...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Yu, Yiyi, Guo, Mengzhou, Wei, Ye, Yu, Shan, Li, Hong, Wang, Yan, Xu, Xiaojing, Cui, Yuehong, Tian, Jiawen, Liang, Li, Peng, Ke, Liu, Tianshu
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5348362/
https://ncbi.nlm.nih.gov/pubmed/27825133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13105
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados